IGC Pharma (IGC) Cash from Financing Activities (2010 - 2025)
IGC Pharma (IGC) posted quarterly Cash from Financing Activities of $3.1 million for Q3 2025, up 291.69% year-over-year from $794000.0 in Q3 2024, and up 265.45% quarter-over-quarter from $851000.0 in Q2 2025.
IGC Pharma (IGC) Cash from Financing Activities (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported Cash from Financing Activities for 16 consecutive years, with $3.1 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Cash from Financing Activities rose 291.69% year-over-year to $3.1 million; the TTM figure through Sep 2025 stood at $5.1 million (up 28.84% YoY), while the FY2026 annual figure was $710000.0, down 84.05% from the prior year.
- Cash from Financing Activities advanced to $3.1 million in Q3 2025 per IGC's latest filing, from $851000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $14.2 million in Q1 2021 and bottomed at -$1000.0 in Q4 2021.
- Historically, Cash from Financing Activities has averaged $1.7 million across 5 years, with a median of $696500.0 in 2021.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 100.14% — and 2024, when it jumped 250800.0%.
- IGC Pharma's Cash from Financing Activities stood at -$1000.0 in 2021, then surged by 10300.0% to $102000.0 in 2022, then tumbled by 100.98% to -$1000.0 in 2023, then soared by 34600.0% to $345000.0 in 2024, then jumped by 801.45% to $3.1 million in 2025.
- Business Quant data shows IGC's Cash from Financing Activities at $3.1 million in Q3 2025, $851000.0 in Q2 2025, and $805000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | IGC Pharma | 30.17 Mn | 29.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3.11 Mn |
| Sep 30, 2025 | 3.11 Mn |
| Jun 30, 2025 | 851,000.00 |
| Jun 30, 2025 | 851,000.00 |
| Mar 31, 2025 | 805,000.00 |
| Mar 31, 2025 | 805,000.00 |
| Dec 31, 2024 | 345,000.00 |
| Dec 31, 2024 | 345,000.00 |
| Sep 30, 2024 | 794,000.00 |
| Sep 30, 2024 | 794,000.00 |
| Jun 30, 2024 | 2.51 Mn |
| Jun 30, 2024 | 2.51 Mn |
| Mar 31, 2024 | 667,000.00 |
| Mar 31, 2024 | 667,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Sep 30, 2023 | 2.86 Mn |
| Sep 30, 2023 | 2.86 Mn |
| Jun 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -1,000.00 |